Medical oncologists administer anticancer drug regorafenib to try to improve overall survival in patients with metastatic colorectal cancer who have ceased to respond to standard therapy. However, some of the adverse events related to the use of this drug often limits its use in clinical practice.
Researchers at the University of California, Irvine, have developed and tested on mice a therapeutic treatment that uses engineered stem cells to target and kill cancer bone metastases while preserving the bone.
Cancer took more than 8.7 million years of life and $94.4 billion in lost earnings among people ages 16 to 84 in the United States in 2015. The calculation comes from a new report by American Cancer Society researchers that appears early online in JAMA Oncology.
A team of researchers from UCLA and the University of Toronto have identified a new biomarker found in urine that can help detect aggressive prostate cancer, potentially saving hundreds of thousands of men each year from undergoing unnecessary surgeries and radiotherapy treatments.
Bristol-Myers Squibb Co. announced topline results from CheckMate-459, randomized phase III study evaluating Opdivo (nivolumab) vs. sorafenib as a first-line treatment in patients with unresectable hepatocellular carcinoma.
Prestige BioPharma announced positive top-line results from a phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics of biosimilar candidate HD201 to Herceptin (trastuzumab).
Myriad Genetics Inc. announced the publication of results from a large study that demonstrated the Prolaris test can accurately predict the 10-year risk of metastases in men newly diagnosed with localized prostate cancer. The study was published in journal Prostate Cancer and Prostatic Diseases.
The National Comprehensive Cancer Network announced the newly-published NCCN Guidelines for Patients: Bladder Cancer, created with funding through the NCCN Foundation.
A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the U.S. The report, appearing as a Research Letter in JAMA Oncology, finds one in six survivors (16%), representing about 2.5 million people in the U.S., reported suffering from high impact chronic pain that restricts daily functioning. Those rates are about double the rates in the general population.
The standard of care for women with stage III/IVA endometrial cancer following surgery has been chemotherapy and radiation to prevent recurrence. But in a new finding, radiation combined with chemotherapy did not increase recurrence-free survival in these women.
